DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Fasching PA, Jackisch C, Rhiem K. et al.
GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).
J Clin Oncol 2019;
37: 506
doi:10.1200/JCO.2019.37.15_suppl.506
Access:
We do not assume any responsibility for the contents of the web pages of other providers.